Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%)
majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq:
SRNE, “Sorrento”), a commercial biopharmaceutical company focused
on developing and commercializing non-opioid therapies for patients
with acute and chronic pain, announced that it will be presenting
SP-102 (SEMDEXA™) efficacy and safety data from its Pivotal Phase 3
clinical C.L.E.A.R trial program (Corticosteroid Lumbosacral
Epidural Analgesia for Radiculopathy) for sciatica pain management
at the 24th Annual Meeting of American Society of Interventional
Pain Physicians (ASIPP) on May 5, 2022 in Las Vegas, NV.
The podium presentation will describe the Phase 3 trial, known
as the C.L.E.A.R. trial program, randomized 401 lumbosacral
radicular pain/sciatica patients at 40 sites across 25 states in
the U.S., which is the largest double-blind randomized controlled
Phase 3 epidural steroid injection clinical trial in
sciatica.
Presenting Author: Prof. Dr. Nebojsa
Nick Knezevic, M.D., Ph.D., Professor of Anesthesiology and
Surgery, College of Medicine, University of Illinois at Chicago,
President of the Illinois Society of Interventional Pain
Physicians, Director-at-Large of the North American Society of
Neuromodulation, Vice-Chair for Research and Education, Advocate
Illinois Masonic Medical Center, Department of Anesthesiology and
Pain Management.
The presentation will be during
Innovation Summit session at ASIPP on May 5, 2022 at 5:05PM ET to
5:20PM ET, and will describe the outcome of the C.L.E.A.R.
trial.
“It has been a while since new drugs have been developed for
interventional pain procedures. We are anxiously awaiting a new
injectable formulation of viscous gel dexamethasone with extended
local effect and its FDA approval for the treatment of radicular
pain based on the results of a large randomized multicenter
placebo-controlled trial. If approved by the FDA, it will be the
first corticosteroid ever approved for epidural injections
addressing safety issues with steroid medications that have been
used off-label in the past few decades. This could be an important
addition to treatment options for these patients, a game-changer,”
said Prof. Dr. Nebojsa Nick Knezevic, M.D., Ph.D..
Scilex Holding Company and Vickers Vantage Corp.
I (Nasdaq: VCKA) (“VCKA”), a special purpose acquisition company
sponsored by Vickers Venture Fund VI Pte Ltd and Vickers Venture
Fund VI (Plan) Pte Ltd, entered into a definitive business
combination agreement ("BCA") on March 17, 2022. Upon the closing
of the transaction, the combined company (the “Combined Company”)
will be renamed Scilex Holding Company, and its common stock is
expected to be listed on Nasdaq under the ticker symbol “SCLX”. The
boards of directors of each of VCKA, Scilex and Sorrento have
unanimously approved the proposed transaction. The closing of the
transaction, which is expected to occur by the third quarter of
2022, is subject to the approval of VCKA’s shareholders and the
satisfaction or waiver of certain other customary closing
conditions.
A corporate presentation describing Scilex's development plans
can be found at www.scilexholding.com.
About Scilex Holding Company
Scilex Holding Company, a nearly 100% (or over
99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc., is
dedicated to the development and commercialization of non-opioid
pain management products for treatment of acute and chronic pain.
Scilex is uncompromising in its focus to become the global pain
management leader committed to social, environmental, economic, and
ethical principles to responsibly develop pharmaceutical products
to maximize quality of life. Highly positive results from the Phase
III Pivotal Trial C.L.E.A.R Program for SEMDEXA™, its novel,
non-opioid product for the treatment of lumbosacral radicular pain
(sciatica), were announced in March 2022. Scilex targets
indications with high unmet needs and large market opportunities
with non-opioid therapies for the treatment of patients with
moderate to severe pain. Scilex launched its first commercial
product in October 2018 and is developing its late-stage pipeline,
which includes a pivotal Phase 3 candidate and one Phase 2 and one
Phase 1 candidate. Its commercial product, ZTlido® (lidocaine
topical system) 1.8%, or ZTlido®, is a prescription lidocaine
topical product approved by the U.S. Food and Drug Administration
for the relief of pain associated with postherpetic neuralgia,
which is a form of post-shingles nerve pain. Scilex’s three product
candidates are SP-102 (injectable dexamethasone sodium phosphate
viscous gel product containing 10 mg dexamethasone), or SEMDEXA™, a
Phase 3, novel, viscous gel formulation of a widely used
corticosteroid for epidural injections to treat lumbosacral
radicular pain, or sciatica, with FDA Fast Track status; SP-103
(lidocaine topical system) 5.4%, a Phase 2, triple-strength
formulation of ZTlido®, for the treatment of low back pain; and
SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone
Hydrochloride (DBR-LDN) Capsule, for the treatment of chronic pain,
fibromyalgia in multiple Phase 1 programs expected to be initiated
this year. For further information regarding the SP-102 Phase 3
efficacy trial, see NCT identifier NCT03372161 - Corticosteroid
Lumbar Epidural Analgesia for Radiculopathy - Full Text View -
ClinicalTrials.gov.
Scilex Holding Company is headquartered in Palo Alto,
California, with operations in both Palo Alto and San Diego,
California. For further information please visit
www.scilexholding.com.
About Sorrento Therapeutics, Inc.
Sorrento is a clinical and commercial stage
biopharmaceutical company developing new therapies to treat cancer,
pain (non-opioid treatments), autoimmune disease and COVID-19.
Sorrento's multimodal, multipronged approach to fighting cancer is
made possible by its extensive immuno-oncology platforms, including
key assets such as fully human antibodies (“G-MAB™ library”),
immuno-cellular therapies (“DAR-T™”), antibody-drug conjugates
(“ADCs”), and oncolytic virus (“Seprehvec™”). Sorrento is also
developing potential antiviral therapies and vaccines against
coronaviruses, including Abivertinib, COVI-AMG™, COVISHIELD™,
COVI-MSC™ and COVIDROPS™; and diagnostic test solutions, including
COVITRACK™ and COVIMARK™.
Sorrento's commitment to life-enhancing
therapies for patients is also demonstrated by our effort to
advance a first-in-class (TRPV1 agonist) non-opioid pain management
small molecule, resiniferatoxin (“RTX”), and SP-102 (10 mg,
dexamethasone sodium phosphate viscous gel) (SEMDEXA™), a novel,
viscous gel formulation of a widely used corticosteroid for
epidural injections to treat lumbosacral radicular pain, or
sciatica, and to commercialize ZTlido® (lidocaine topical system)
1.8% for the treatment of postherpetic neuralgia (PHN). RTX has
been cleared for a Phase II trial for intractable pain associated
with cancer and a Phase II trial in osteoarthritis patients.
Positive final results from the Phase III Pivotal Trial C.L.E.A.R.
Program for SEMDEXA™, its novel, non-opioid product for the
treatment of lumbosacral radicular pain (sciatica), were announced
in March 2022. ZTlido® was approved by the FDA on February 28,
2018.
For more information visit
www.sorrentotherapeutics.com
About Vickers Vantage Corp. I
Vickers Vantage Corp. I is a blank check company
formed for the purpose of effecting a merger, share exchange, asset
acquisition, share purchase, reorganization or similar business
combination with one or more businesses or entities.
Important Information for Investors and
Stockholders
This press release relates to a proposed transaction between
Scilex and VCKA. This press release does not constitute an offer to
sell or exchange, or the solicitation of an offer to buy or
exchange, any securities, nor shall there be any sale of securities
in any jurisdiction in which such offer, sale or exchange would be
unlawful prior to registration or qualification under the
securities laws of any such jurisdiction. In connection with the
transaction described herein, VCKA intends to file relevant
materials with the SEC, including a registration statement on Form
S-4, which will include a document that serves as a prospectus and
proxy statement of VCKA, referred to as proxy statement/prospectus.
After the registration statement is declared effective by the SEC,
the proxy statement/prospectus will be sent to all VCKA
shareholders as of a record date for the meeting of VCKA
shareholders to be established for voting on the proposed business
combination. VCKA will also file other documents regarding the
proposed transaction with the SEC. This press release does not
contain all of the information that will be contained in the proxy
statement/prospectus or other documents filed or to be filed with
the SEC. Investors and security holders of VCKA are urged
to read these materials (including any amendments or supplements
thereto) and any other relevant documents in connection with the
transaction that VCKA files with the SEC when, and if, they become
available because they will contain important information about
VCKA, Scilex and the proposed transaction. Investors
and security holders will be able to obtain free copies of the
registration statement, the proxy statement/prospectus and all
other relevant documents filed or that will be filed with the SEC
by VCKA through the website maintained by the SEC at
www.sec.gov.
Participants in the Solicitation
VCKA and its directors and executive officers may be deemed
participants in the solicitation of proxies from VCKA’s
shareholders in connection with the transaction. A list of the
names of such directors and executive officers and information
regarding their interests in the proposed business combination will
be contained in the proxy statement/prospectus when available. You
may obtain free copies of these documents as described in the
preceding paragraph.
Scilex and its directors and executive officers
may also be deemed to be participants in the solicitation of
proxies from the shareholders of VCKA in connection with the
proposed transaction. Information about Scilex’s directors and
executive officers and information regarding their interests in the
proposed transaction will be included in the proxy
statement/prospectus for the proposed transaction.
Non-Solicitation
This press release is not a proxy statement or
solicitation of a proxy, consent or authorization with respect to
any securities or in respect of the potential transaction and shall
not constitute an offer to sell or a solicitation of an offer to
buy the securities of VCKA, the Combined Company or Scilex, nor
shall there be any sale of any such securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of such state or jurisdiction. No offer of
securities shall be made except by means of a prospectus meeting
the requirements of the Securities Act of 1933, as amended.
Forward-Looking Statements
This press release and any statements made for
and during any presentation or meeting concerning the matters
discussed in this press release contain forward-looking statements
related to VCKA, Sorrento Therapeutics, Inc. and its subsidiaries,
including but not limited to Scilex, under the safe harbor
provisions of Section 21E of the Private Securities Litigation
Reform Act of 1995 and are subject to risks and uncertainties that
could cause actual results to differ materially from those
projected. Forward-looking statements include statements regarding
the proposed business combination between Scilex and VCKA,
including the timing of such business combination, the potential
listing of the Combined Company’s common stock on Nasdaq or other
major securities exchange and the anticipated stock ticker symbol
for such shares, the expectation that VCKA will file a registration
statement on Form S-4 with the SEC, which would include a
proxy statement/prospectus, the estimated or anticipated future
results and benefits of the Combined Company following the proposed
business combination, including the likelihood and ability of the
parties to successfully consummate the proposed business
combination, future opportunities for the Combined Company, the
timing of the completion of the proposed business combination,
Scilex’s and the Combined Company’s proposed business strategies,
the expected cash resources of the Combined Company and the
expected uses thereof; Scilex’s and the Combined Company’s current
and prospective product candidates, planned clinical trials and
preclinical activities and potential product approvals, as well as
the potential for market acceptance of any approved products and
the related market opportunity; statements regarding SP-102
(SEMDEXA™), if approved by the FDA; Scilex’s development and
commercialization plans; and Sorrento’s products, technologies and
prospects and Scilex’s products, technologies and prospects,
including the potential for Scilex’s product candidates to be
best-in-class or first-in-class therapies. Risks and
uncertainties that could cause Sorrento’s and Scilex’s actual
results to differ materially and adversely from those expressed in
our forward-looking statements, include, but are not limited to:
the inability of the parties to consummate the proposed business
combination transaction for any reason or the occurrence of any
event, change or other circumstances that could give rise to the
termination of the BCA, including any failure to meet applicable
closing conditions; changes in the structure, timing and completion
of the proposed transaction between VCKA and Scilex; VCKA’s ability
to continue its listing on the Nasdaq Capital Market until closing
of the proposed transaction; the Combined Company’s ability to list
its securities on Nasdaq or other major securities exchange after
closing of the proposed transaction; the ability of the parties to
achieve the benefits of the proposed transaction, including future
financial and operating results of the Combined Company; the
ability of the parties to realize the expected synergies from the
proposed transaction; risks related to the outcome of any legal
proceedings that may be instituted against the parties following
the announcement of the proposed business combination; general
economic, political and business conditions; risks related to the
ongoing COVID-19 pandemic; the risk that the potential product
candidates that Scilex develops may not progress through clinical
development or receive required regulatory approvals within
expected timelines or at all; risks relating to uncertainty
regarding the regulatory pathway for Scilex’s product candidates;
the risk that Scilex will be unable to successfully market or gain
market acceptance of its product candidates; the risk that Scilex’s
product candidates may not be beneficial to patients or
successfully commercialized; the risk that Scilex has overestimated
the size of the target patient population, their willingness to try
new therapies and the willingness of physicians to prescribe these
therapies; risks that the prior results of the clinical trials of
SP-102 (SEMDEXA™) may not be replicated; regulatory and
intellectual property risks; the risk that any requisite regulatory
approvals to complete the transaction are not obtained, are delayed
or are subject to unanticipated conditions that could adversely
affect the Combined Company or the expected benefits of the
proposed transaction or that the approval of VCKA’s shareholders is
not obtained; the risk of failure to realize the anticipated
benefits of the proposed transaction; the amount of redemption
requests made by VCKA’s shareholders and other risks and
uncertainties indicated from time to time and other risks set forth
in Sorrento’s and VCKA’s filings with the SEC. Investors are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this release, and we
undertake no obligation to update any forward-looking statement in
this press release except as may be required by law.
Contacts:
For Scilex Holding Company
Jaisim ShahChief Executive OfficerScilex Holding Company 960 San
Antonio RoadPalo Alto, CA 94303Office: (650) 516-4310Email:
jshah@scilexpharma.com
Website: www.sorrentotherapeutics.com and
www.scilexholding.com
Investors and Media Contact:
Contact: Brian Cooley
Senior Vice PresidentCorporate Communications and Investor
RelationshipsHead of Lymphatic Drug DeliveryEmail:
mediarelations@sorrentotherapeutics.comWebsite:
www.sorrentotherapeutics.com
For Vickers Vantage Corp. I
Jeffrey Chi Chief Executive Officer 85 Broad Street, 16th
FloorNew York, NY 10004Phone: (646) 974-8301Email:
jeff.chi@vickersventure.com
Website: www.vickersvantage.com
Investors and Media Contact: Nicolette Ten, Senior Account
Executive, SPRGEmail: nicolette.ten@sprg.com.sg
Sorrento® and the Sorrento logo are registered
trademarks of Sorrento Therapeutics, Inc.
G-MAB™, DAR-T™, Seprehvec™, SOFUSA™, COVI-AMG™,
COVISHIELD™, COVIDROPS™, COVI-MSC™, COVITRACK™ and COVIMARK™ are
trademarks of Sorrento Therapeutics, Inc.
SEMDEXA™ (SP-102) is a trademark owned by Semnur
Pharmaceuticals, Inc., a wholly owned subsidiary of Scilex Holding
Company. A proprietary name review by the FDA is planned.
ZTlido® is a registered trademark owned by
Scilex Pharmaceuticals Inc., a wholly owned subsidiary of Scilex
Holding Company.
All other trademarks are the property of their
respective owners.
© 2022 Sorrento Therapeutics, Inc. All Rights
Reserved.
Sorrento Therapeutics (NASDAQ:SRNE)
Historical Stock Chart
From Apr 2024 to May 2024
Sorrento Therapeutics (NASDAQ:SRNE)
Historical Stock Chart
From May 2023 to May 2024